Ece Cali Daylan, MD, PhD Profile
Ece Cali Daylan, MD, PhD

@ececalidaylan

Followers
341
Following
978
Media
4
Statuses
83

Thoracic oncologist 🫁 @wustl @sitemancenter via @montefioreNYC @einsteinmed

St Louis, MO
Joined January 2022
Don't wanna be here? Send us removal request.
@IASLC
IASLC
2 months
Thoracic Circle is LIVE! 🎉 A new space to connect, share, and grow with the #IASLC community — anytime, anywhere. Check your inbox or start here: https://t.co/2nrqbXjwNI @hivebrite
3
20
49
@MikkaelSekeres
Mikkael A. Sekeres MD, MS
5 months
Announcing the first EVER @JCO_ASCO Art of Oncology Narrative Medicine Contest! 🎉✍️🎗️🩺🎉 We're looking for essays that explore the human experience of cancer and reflect on the experience of trainees and early career hematologists/oncologists. Apply Now!
Tweet card summary image
ascopubs.org
5
34
91
@ececalidaylan
Ece Cali Daylan, MD, PhD
7 months
EGFR mutant akciğer kanseri hakkında hem güncel hem de çok keyifli bu sohbeti kaçırmayın @CkapSaadettin #akciğerkanseri #EGFR #onkoloji
@IASLC
IASLC
7 months
Catch the #LungCancerConsidered episode in Turkish! 🇹🇷 Explore first-line therapies for EGFR-mutant NSCLC with @ececalidaylan, Dr. Özden Altundağ & Dr. Saadettin Kiliçkap. 🎧 Listen now:
0
0
2
@DrJNaidoo
Jarushka Naidoo
1 year
#ESMO24 Lung mini-orals🔥 Randomised ph II trial of inhaled corticosteroids in stage III NSCLC treated with cCRT, to reduce radiation pneumonitis: - 292pts - 15% reduction in RP - no long-term steroid tox No need for ph III, could do tomorrow #ESMOAmbassadors #ESMO24 @myESMO
7
57
158
@TLCconference
TLC Conference
1 year
The 3rd Annual #TexasLung25 will feature even more faculty than ever before! Mark your calendar to join us April 10-12, 2025 for this 2-day CME/CE meeting in Austin, TX. Be part of the discussions and meet leading thoracic oncologists. #MedEd #LungCancer #CME #CE
2
5
15
@StephenVLiu
Stephen V Liu, MD
1 year
The #WCLC24 Photo Gallery caught some great pics of the incredibly knowledgable contestants on our Meet The Expert Quiz Show! Thanks again to Drs. Natasha Leighl, @bensolomon1 @ececalidaylan @g_mountzios @JessicaJLinMD @zaccoyne and Brinda Gupta!
3
14
56
@MyriamChalabi
Myriam Chalabi
1 year
Honored and excited to be scientific co-chair of #ESMO25 together with @DrChoueiri With @FAndreMD as incoming @myESMO president on our side we will be giving it our all! See you in #Berlin 🙏 @RebeccaDSing for a fantastic, practice-changing #ESMO24. We learn from the best ❗️❗️
7
20
176
@JessicaJLinMD
JessicaJLinMD
1 year
🌟And here with the efficacy and safety data of #NVL655, ALK-selective, TRK-sparing and brain-penetrant 4G ALK TKI, from ALKOVE-1, presented today #ESMO24 by @alexdrilon ✅ ORR 38% in heavily pretreated pts overall (1-5 prior ALK TKIs) ✅ ORR 35% in pts post-lorlatinib (in which
1
33
86
@StephenVLiu
Stephen V Liu, MD
1 year
Very nice discussion on relapsed #SCLC by Dr. @Arohatgi at #WCLC24. ADCs showing promise and easier to deliver than a BiTE like tarlatamab. No clear biomarker but encouraging efficacy. But we need randomized data to provide clear perspective.
0
12
31
@RManochakian
Rami Manochakian MD, FASCO Cancer Education
1 year
🔥🚨@OncoAlert HOT OFF THE PRESS. Just presented at the presidential symposium @IASLC #WCLC24 Results of #HARMONi2 trial of #Ivonescimab VS #Pembrolizumab in advanced non-small cell #LungCancer with PD-L1 >1%. ✅ Significant ⬆️mPFS 11.14 vs. 5.82 months (HR 0.51) #Benefit
3
42
100
@ececalidaylan
Ece Cali Daylan, MD, PhD
1 year
Learning from a mentor indeed never ends, whether it's diving into oncology or savoring Nola food! 🐊 Incredibly lucky to have had Balazs guiding me at the start of my thoracic oncology journey and excited to have him as my first visitor in St. Louis!
@BalazsHalmosMD
Balazs Halmos
1 year
Mentorship 101: Important to check on your mentees even after they start a new job- like Eçe at Wash U- even if one has to drive 1000+ miles for it!😉 I took the effort to introduce her to new skills, like eating alligator tacos.. Great to see you taking a fantastic start, Eçe!
2
0
11
@JCO_ASCO
Journal of Clinical Oncology
1 year
#JCO welcomes our onboarding editorial fellows, Ayse Ece Cali Daylan, @MSHughes_MD, Peter Li, Joseph Mathew & @lcshihmd!
0
5
20
@sitcancer
Society for Immunotherapy of Cancer
1 year
#SITC SCION 2025 equips participants with insights into #cancer #immunotherapy #clinical #trials & offers guidance from industry leaders. Expand your network & refine your clinical trial protocol from Feb. 11–14, 2025 in Austin. Apply by July 22: https://t.co/Pb8lMVYgBs
1
2
2
@andyjminn
Andy Minn
1 year
Summary of our paper https://t.co/1CE0c2kHUO on combining JAK inhibitors with anti-PD1 for lung cancer (NSCLC). Part of a bench-to-bedside journey to understand opposing roles of IFN in IO. Wonderful team w @EJohnWherry @divijmathew Caitlin Foley @MMarmarelis @Jbauml et al! 1/13
12
43
160
@ASCOTECAG
ASCO TECAG
1 year
🚨Are you ➡️graduating⬅️ Hematology-Fellowship this month and worried about losing access to @ASCO-SEP before your boards? ⏳ Contact ➡️professionaldevelopment@asco.org once your subscription expires to obtain an extended 12-month subscription for $49, instead of $275! 🌟
1
16
24
@MontefioreNYC
Montefiore Health System
1 year
Congratulations to the three researchers recognized by the Montefiore Staff & Alumni Association! They received the Henry L. Moses Awards in recognition of their exceptional clinical papers and contributions to healthcare. #MonteProud @EinsteinMed
0
4
19
@BalazsHalmosMD
Balazs Halmos
1 year
Hem/onc-there’s no core curriculum. The entire experience is an elective Outstanding class @MontefioreNYC @EinsteinMed has chosen this elective as life mission-wish you’ll best of luck with half staying in Monte circles/others moving on to great things as far as Wash U/Jefferson!
1
4
21
@pulmoncdoc
Dr. Aditi Singh
1 year
0
11
35
@LaurenByersMD
Lauren Averett Byers, MD
1 year
POP QUIZ: Is this a waterfall plot for a new lung cancer TKI? Nope…SEZ6 ADC for Relapsed Small Cell Lung Cancer (and other NECs). #SCLC #LCSM. @MDAndersonNews Thank you to the study team and all of our investigators, patients and families. @ASCO #ASCO24
2
31
105